Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
The Achieva 3.0T TX expands the range of 3T applications possible with routine scanning through higher speed and better image quality using a novel technology dubbed MultiTransmit RF management. This technology automatically adjusts the RF signal to the specific body habitus and anatomy of the patient being scanned. The results, according to Philips, are higher acquisition speed, as well as better image quality and consistency. Together they offer new clinical possibilities for scanning the breast, liver, pelvis, and spine at 3T, according to the company.
Philips extended its current 1.5T platform with the Achieva SE, a scanner designed for budget-constrained customers. The scanner combines high-performance imaging and low capital cost through a sub-$1 million price tag, lower operating costs, and compact siting. The same basic platform drives both the Achieva SE and the high-end Achieva 1.5T A-Series, but the new product is repackaged without the more advanced clinical capabilities of the A-Series. Power-saving features reduce energy consumption -- and energy costs -- by up to 50%, according to Philips.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.